Oasmia Pharmaceutical AB is a Sweden-based pharmaceutical company engaged in the field of human and veterinary oncology. The Company’s activities are divided into two segments: Human Health and Animal Health. The Human Health segment specializes in ovarian and breast cancer. The Animal Health area focuses on developing cancer treatments for dogs. Its drugs portfolio comprises six candidates: Paclical, Doxophos, Docecal and OAS-19, which are implemented in human treatment, as well as Paccal Vet-CA1 and Doxophos Vet, introduced in cancer in dogs. The Company’s medicines are based on the patented XR-17 excipient, which forms micelles with water-soluble substances. Furthermore, It cooperates with Abbott Laboratories, Pharmasyntez, Nippon Zenyaku Kogyo and Medison Pharma. The Company is a parent of Oasmia Global Supplies AB and Oasmia Animal Health AB.